STAAR Surgical Files 8-K/A Amendment

TL;DR

STAAR Surgical filed an amendment to its 8-K, updating financial and regulatory disclosures.

AI Summary

STAAR Surgical Company filed an 8-K/A on October 31, 2024, to amend a previous filing. The amendment pertains to the "Results of Operations and Financial Condition" and "Regulation FD Disclosure" as of October 30, 2024. The filing is related to their financial reporting and disclosures.

Why It Matters

This filing indicates an update or correction to previously disclosed financial information or regulatory disclosures, which could impact investor understanding of the company's financial health.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, likely for clarification or correction, and does not appear to introduce new material events.

Key Players & Entities

• STAAR Surgical Co (company) — Registrant
• October 30, 2024 (date) — Date of earliest event reported
• October 31, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of Incorporation
• 626 - 303-7902 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $340 million — tlook for fiscal year 2024 net sales of $340 million to $345 million, as set forth in the pr
• $345 m — year 2024 net sales of $340 million to $345 million, as set forth in the press releas

Filing Documents

• staa-20241030.htm (8-K/A) — 46KB
• staa-ex99_1.htm (EX-99.1) — 1538KB
• staa-ex99_2.htm (EX-99.2) — 23KB
• img177331332_0.jpg (GRAPHIC) — 11KB
• staa-ex99_2s1.jpg (GRAPHIC) — 168KB
• staa-ex99_2s2.jpg (GRAPHIC) — 308KB
• staa-ex99_2s3.jpg (GRAPHIC) — 485KB
• staa-ex99_2s4.jpg (GRAPHIC) — 630KB
• staa-ex99_2s5.jpg (GRAPHIC) — 673KB
• staa-ex99_2s6.jpg (GRAPHIC) — 392KB
• staa-ex99_2s7.jpg (GRAPHIC) — 406KB
• staa-ex99_2s8.jpg (GRAPHIC) — 394KB
• staa-ex99_2s9.jpg (GRAPHIC) — 236KB
• staa-ex99_2s10.jpg (GRAPHIC) — 228KB
• staa-ex99_2s11.jpg (GRAPHIC) — 190KB
• staa-ex99_2s12.jpg (GRAPHIC) — 221KB
• staa-ex99_2s13.jpg (GRAPHIC) — 237KB
• staa-ex99_2s14.jpg (GRAPHIC) — 292KB
• staa-ex99_2s15.jpg (GRAPHIC) — 345KB
• staa-ex99_2s16.jpg (GRAPHIC) — 425KB
• staa-ex99_2s17.jpg (GRAPHIC) — 413KB
• 0000950170-24-119230.txt ( ) — 10108KB
• staa-20241030.xsd (EX-101.SCH) — 29KB
• staa-20241030_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 30, 2024, STAAR Surgical Company (the "Company") reported its financial results for the quarter ended September 27, 2024, and filed a Current Report on Form 8-K (the "Original Form 8-K"), which included the Company's earnings press release as Exhibit 99.1 and the Company's slide presentation as Exhibit 99.2. As further discussed below in Item 7.01, the Company is filing this Current Report on Form 8-K/A to amend the Original Form 8-K to correct inconsistencies in the press release and the slide presentation regarding assumptions underlying the Company's financial outlook for fiscal year 2024 related to APAC regional growth rates.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 30, 2024, the Company published an updated press release and an updated slide presentation to correctly reflect the Company's assumptions underlying its financial outlook for fiscal year 2024 related to APAC regional growth rates. No other changes were made to the press release or the slide presentation furnished as exhibits to the Original Form 8-K. A copy of the updated press release is furnished herewith as Exhibit 99.1, and a copy of updated slide presentation is furnished herewith as Exhibit 99.2. The Company's outlook for fiscal year 2024 net sales of $340 million to $345 million, as set forth in the press release and slide presentation, is unchanged. The updated press release and updated slide presentation reflect the following assumptions underlying such outlook: EVO ICL sales growth of 17% in the Americas (prior outlook was 15%) including 20% in the U.S. (prior outlook was 25%); EMEA sales growth of 10% (prior outlook was 6%); and APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). The information contained in this Form 8-K/A and the exhibits hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Form 8-K/A, Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Form 8-K/A, regardless of any general incorporation language in the filing. The Company's financial outlook for fiscal year 2024, including the assumptions underlying such outlook, are forward-looking statements. Important factors that could cause actual results to differ materially from those

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of the Company dated October 30, 2024 (updated). 99.2 Slide presentation of the Company dated October 30, 2024 (updated). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company October 30, 2024 By: /s/ Tom Frinzi Thomas G. Frinzi President and Chief Executive Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR